Celgene Corporation is a biopharmaceutical company specializing in the development and commercialization of cancer and immunology drugs. Its major product is Revlimid (lenalidomide), used in the treatment of multiple myeloma and certain anemias.

Sol Barer

Robert J. Hariri

Celgene Corporation

DeuteRx is involved in improving medicines for patients. This description is self-described.

DeuteRx

Aster Insights partners with drug, biologics, diagnostics, and medical device developers to accelerate oncology product discovery and development through scientific and clinical intelligence.

Aster Insights

Oruka Therapeutics is focused on improving the experiences of people living with plaque psoriasis, psoriatic arthritis, and other dermatologic and inflammatory indications. Self-described as committed to advancing potentially best-in-class monoclonal antibodies for treatment.

Metric
Company Name	Celgene Corporation	DeuteRx	Aster Insights	Oruka Therapeutics
Symbol
MSH ID	COM:CELGENE	COM:DEUTERX	COM:M2GEN	COM:ORUKATX
Market	PRIVATE	PRIVATE	PRIVATE	PRIVATE
Sector	Healthcare & Health Services	Healthcare & Health Services	Healthcare & Health Services	Healthcare & Health Services
Industry	Biotechnology	Pharmaceuticals	Biotechnology	Biotechnology
Country		US	US	US
Stage				Post-IPO Equity
Employee Count	10.00K
Website	celgene.com	deuterx.com	m2gen.com	orukatx.com
LinkedIn		deuterx		oruka-therapeutics
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic				1.26K
Web Traffic Growth				0.67
Valuation
Raised Capital				275M

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

CELG

COM:CELGENE

Celgene Corporation

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue